Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM

We have evaluated the effects of repaglinide, a new non-sulphonylurea oral hypoglycaemic agent that has a stimulatory effect on insulin secretion. Forty-four patients with NIDDM, already treated with a sulphonylurea, took part in an open, randomised, group comparison study of 12 weeks duration, duri...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical pharmacology 1993-09, Vol.45 (2), p.113-116
Main Authors: WOLFFENBUTTEL, B. H. R, NIJST, L, SELS, J. P. J. E, MENHEERE, P. P. C. A, MÜLLER, P. G, NIEUWENHUIJZEN KRUSEMAN, A. C
Format: Article
Language:English
Subjects:
Aged
Biological and medical sciences
Blood Glucose - analysis
Carbamates - blood
Carbamates - pharmacology
Carbamates - therapeutic use
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - drug therapy
Female
Fructosamine
General and cellular metabolism. Vitamins
Gliclazide - therapeutic use
Glyburide - blood
Glyburide - pharmacology
Glyburide - therapeutic use
Glycated Hemoglobin A - analysis
Hexosamines - blood
Humans
Hypoglycemic Agents - pharmacology
Lipids - blood
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Piperidines - blood
Piperidines - pharmacology
Piperidines - therapeutic use
Tolbutamide - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We have evaluated the effects of repaglinide, a new non-sulphonylurea oral hypoglycaemic agent that has a stimulatory effect on insulin secretion. Forty-four patients with NIDDM, already treated with a sulphonylurea, took part in an open, randomised, group comparison study of 12 weeks duration, during which they received either repaglinide or glibenclamide twice daily. While glibenclamide had a greater effect on fasting blood glucose (10.4 to 8.6 mmol.l-1), repaglinide significantly lowered postprandial blood glucose (13.8 to 12.2 mmol.l-1). Glycosylated haemoglobin remained unchanged in both groups, and serum fructosamine showed a tendency to fall. With both treatments total cholesterol was significantly decreased after 12 weeks, while HDL-cholesterol and triglycerides did not change. Fasting plasma insulin in the repaglinide group decreased from 80 (median value) to 67 pmol.l-1; it did not change in the glibenclamide group. Two patients in the repaglinide group did not complete the study, one for personal reasons, and one because of a rise in blood glucose. No abnormal findings attributable to repaglinide were observed in clinical and laboratory examinations, and no hypoglycaemic symptoms caused by it were observed.
ISSN:0031-6970
1432-1041
DOI:10.1007/BF00315490